FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to pharmacology, and concerns new chemical compounds of general formula (I) or their pharmaceutically acceptable salts which are inhibitors of P-glycoprotein. In formula (I) R1, R2, R3, R4 independently represent H, halogen, NO2; Rx - is selected from -C(=S)NHRA, -C(=O)ORA, -S(=O)2NRARB, -C(=O) NRARB, 5-membered partially or completely unsaturated heterocycle containing 2 N atoms; RA is independently selected and represents C1-6-alkyl, partially or completely halogenated C1-8-alkyl; RB is independently selected and represents H, C1-8-alkyl or partially or completely halogenated C1-8-alkyl; alternatively, in case Rx is -C (= O) NRARB, RA and RB together with nitrogen atom, to which they are attached, can form saturated cycle containing 5 atoms; Rp is independently selected and represents C1-6-alkyl, partially or completely halogenated C1-6-alkyl; Rm is selected independently and is H, C1-6-alkyl, partially or completely halogenated C1-8-alkyl; alternatively neighbouring groups Rp and Rm together with two oxygen atoms, to which they are attached, and two carbon atoms of the benzene ring can form a non-aromatic ring containing 5 to 6 atoms. Given chemical compounds can be used to suppress multiple drug resistance in the patients receiving the various drugs for a long time. Invention also relates to the use of the above compounds and a pharmaceutical composition containing said compounds.
(I).
EFFECT: these compounds can be used in therapy of central nervous system diseases, infectious, allergic, autoimmune, oncological and other diseases.
9 cl
Title | Year | Author | Number |
---|---|---|---|
HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION AND USE THEREOF | 2020 |
|
RU2823875C1 |
NEW CHEMICAL COMPOUNDS (VERSIONS) AND USING THEM FOR TREATING ONCOLOGICAL DISEASES | 2013 |
|
RU2550346C2 |
INHIBITORS OF TYPE ErbB INHIBITORS | 2006 |
|
RU2592703C9 |
N4-PHENYLQUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS RECEPTOR TYROSINE KINASE TYPE ERBB INIHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | 2006 |
|
RU2428421C2 |
SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 2018 |
|
RU2817698C2 |
BENZO[D]ISOXAZOLE DERIVATIVES AND THEIR APPLICATION | 2016 |
|
RU2638155C1 |
HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2022 |
|
RU2811745C1 |
PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
DERIVATIVE OF PYRIMIDINE AND A FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLE, METHOD FOR PRODUCTION AND MEDICAL APPLICATIONS THEREOF | 2019 |
|
RU2775229C1 |
PYRIMIDINE DERIVATIVES AND USE THEREOF IN TREATING RESPIRATORY DISEASES, SUCH AS COPD | 2011 |
|
RU2604719C2 |
Authors
Dates
2019-07-19—Published
2015-05-22—Filed